ASCO Plenary Apr 2022 - ASCO Plenary Series: April 2022
Apr 19 - Apr 19, 2022 | AlexandriaVAUS
LARVOL is not affiliated with ASCO Plenary Series: April 2022 and all trademarks, logos, and brand names are property of their respective owners
Condition
Product
MOA
Trial Name/ID
Showing 1 abstracts linked to Trials
RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.